CooperCompanies (NASDAQ: COO), a leading medical device company, saw its stock plunge 7.95% in after-hours trading on Thursday, March 6, despite reporting solid fiscal first-quarter 2025 results and raising its full-year guidance.
For the quarter ended January 31, 2025, CooperCompanies delivered a 4% year-over-year increase in revenue to $964.7 million, with its CooperVision segment growing 6% organically and CooperSurgical segment up 2% organically. Non-GAAP diluted earnings per share came in at $0.92, up from $0.85 in the prior-year period.
Encouraged by the strong start to the fiscal year, the company raised its full-year 2025 non-GAAP EPS guidance to a range of $3.94 to $4.02, up from its previous outlook of $3.92 to $4.02. Management commented on their confidence in delivering robust growth and operational excellence going forward.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。